LAYER 01 · THE FUTURE

The future it's building

Inflammatory bowel disease is a large market where many patients still need better, more convenient treatments. A successful oral therapy could matter a great deal.

Market size: [data to be added]

LAYER 02 · THE BUILDER

Why Abivax

Abivax is a clinical-stage biotech developing obefazimod, an oral drug candidate for ulcerative colitis. This is not an AI name, and it is our highest-risk position.

LAYER 03 · THE DEEP DIVE

What the full deep dive answers

  • What do the clinical results tell us so far?
  • What is the regulatory path and timeline?
  • How does it compare with existing therapies?
  • How do we size a binary outcome?
Members only

Read the full ABVX deep dive

Full thesis, risks, scenarios and what would change our mind.

Become a memberI'm a member
LAYER 04 · SIGNALS

What the future makers are saying

Latest signal: coming soon.
We track: Clinical trial readouts, regulatory filings.

Disclosure: the EarlyConviction team holds a position in ABVX. This is not investment advice. Content is produced with AI analyst personas. Read the disclaimer.